Corante

About this Author
Derek Lowe
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com

Chemistry and Pharma Blogs:
Pharmalot
Org Prep Daily
On Pharma
One in Ten Thousand
Away From the Bench
QDIS Blog
Chemical Musings
In Vivo Blog
The Chemblog
Molecule of the Day
Kinase Pro
Drugs and Poisons
Jungfreudlich
Chembark
Social Detritus
Pharmagossip
Whistling in the Wind
Organometallic Current
Great Molecular Crapshoot
Post Doc Ergo Propter Doc
A Chemist's Lab Notebook
The Curious Wavefunction Totally Synthetic
Pharma's Cutting Edge
The F- Blog
Synthetic Environment
Atom Pusher
Chemistry World Blog
Carbon-Based Curiosities
Eye on FDA
Hdreioplus
Closeted Chemistry
Chemical Forums
Curly Arrow
Power of Goo
Carbon Tet
Totally Medicinal
Sceptical Chymist
Lamentations on Chemistry
PeterMR
Mining Drugs
Regulatory Affairs of the Heart
Making Graphite Work
Liquid Carbon
Half-Decent Pharma Blog


Science Blogs and News:
The Loom
Uncertain Principles
The Crimson Canary
Fierce Biotech
Blogs for Industry
The Futile Cycle
Omics! Omics!
Young Female Scientist
Notional Slurry
Life of a Lab Rat
TP With Page Numbers
Nobel Intent
SciTech Daily
Is This Thing On?
Science Blog
Eastern Blot
Oncology Updates
FuturePundit
Flags and Lollipops
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Daily Biomed
Voyage to Arcturus
Adventures in Ethics and Science
Terra Sigillata
Transterrestrial Musings
The Mass Spectrometry Blog
Nodal Point
Slashdot Science
A Scientist's Life
Living the Scientific Life
John Johnson
Humans in Science
Tobias Sing's Bioinformatics Blog
Speculist
Science, Shrimp and Grits
Biopeer
Cosmic Variance
The Capsule
Zeroth Order Approximation
Science Library Blog
Biology News Net


Medical Blogs
MedPundit
Med Tech Sentinel
DB's Medical Rants
Dr. Charles
RangelMD
GruntDoc
The Health Care Blog
Cut to Cure
Respectful Insolence
Black Triangle
Diabetes Mine


Economics and Business
Marginal Revolution
Arnold Kling
The Volokh Conspiracy
Knowledge Problem
The Stalwart


Politics / Current Events
Virginia Postrel
Tinkerty Tonk
Instapundit
Asymmetrical Information
Belmont Club
Man Without Qualities
Belgravia Dispatch
Mickey Kaus
Colby Cosh
Progressive Reaction
No Watermelons


Belles Lettres
Two Blowhards
Critical Mass
Arts and Letters Daily
God of the Machine
Armavirumque
About Last Night

In the Pipeline

Date Index
December 2008
01: Prodrugs: How the Pros Do It?

November 2008
26: How Slow is Research Today? Here's a Recipe!
25: Avandia: Trouble, Run Head to Head
24: Two Drugs in One? Maybe Not.
21: The Back Door to the Stock Market
20: Noisy Numbers
19: Novartis and Reality
18: Cheese Dip and Hydrochloric Acid
17: Liable For Generics? You Are Now!
14: Sticking It to Proteins
13: The Yield Monster - And Its Friend, The Model Monster
12: Crestor: Would It Save Any Lives?
11: Wash Your Tubes; Mess Up Your Data
10: Crestor: Risks Up, Risks Down
07: System Biology: Ready, or Not?
06: CB-1 Obesity Drugs: Farewell to the Whole Lot
05: We Now Return to Our Regularly Scheduled Program
04: We Interrupt This Science. . .For Some Politics
03: Pfizer: Strategy, Layoffs, and Money

October 2008
31: Fructose In The Brain?
30: Lilly And Imclone: Not Expensive Enough!
29: Cutbacks - But Not As Bad This Time
28: Out the Door and Down the Stairs
27: Publish And Be Damned, Most Likely
24: BlackLight Power Responds
23: Merck Cuts Back (Again)
22: Blacklight Power: What on Earth?
21: Things I Won't Work With: Triazadienyl Fluoride
20: Fearful Symmetry?
17: Down The Chute in Phase III
16: Animal Models: How High to Set the Bar?
15: Where Are the Drugs?
14: Impact Factors: Can We Pretend That They Don't Exist?
13: Old School - Really Old
10: Kevin Trudeau: A Bit of Good News
09: More Glowing Cells: Chemistry Comes Through Again
08: A Green Fluorescent Nobel Prize
07: Nobel Season 2008
06: Imclone Really Does Get Bought
03: Day Off
02: Taranabant Is No More
02: Eli Lilly and Imclone: Sensible? Real?
01: Hard Times: A Manifesto

September 2008
30: Various Drug Industry News, None of It All That Good
29: Why Don't You Just. . .
26: Prasugrel Today?
26: Imclone's Secret Admirer
25: Pfizer: As We Speak?
25: Protein Folding: Complexity to Make More Complexity?
24: Ariad's Patent: A Court Rules
23: You Call That An X-Ray Source?
22: More Than This
19: Sunesis: No Substitutions Allowed?
17: Sugars: Still Crazy After All These Years
17: Ranbaxy: Cutting Corners, or Falsely Accused?
16: Neil Bartlett, 1932-2008
15: Extracting Money From Matthias Rath, For A Change
12: BMS vs. Imclone: Godzilla Exchanges Legal Language With Mothra
11: US and UK Biotech: Growth and Form
10: Pfizer / Bayer?
09: Antipsychotics: Do They Work For A Completely Different Reason?
08: The Complicated Causes of Cancer
05: Samurai! Unleash Your Drug Candidates!
04: X-Ray Structures: Handle With Care
03: Direct To Consumer Ads: Wasted Money?

August 2008
29: Sticky Containers, Vanishing Drugs
28: PNAS: Read It, or Not?
27: Crowded Proteins
26: New, Improved DNA?
25: How Not To Do It: Water Aspirators
22: Open Source Science?
21: RNAi: Bubble or Not?
20: Replacing What's Being Lost
19: Fighting Boredom, Profitably
18: Genentech and Roche, Act Two
15: Back
05: Roche Palo Alto: What's Going On?
05: Time Off
04: Job Seekers: Genentech, GSK, and Elsewhere
01: GSK Layoffs: Yes, Again

July 2008
31: Rember for Alzheimer's: Methylene Blue's Comeback
30: Bapineuzumab: Good For Anything or Not?
29: Iloperidone: A Schizophrenia Drug Goes Down For the Last Time
28: Questions You Don't Necessarily Want the Answers To . . .
25: Should Genentech Be a Part of Roche?
24: Confident
23: Patents Stopping an Alzheimer's Wonder Drug?
22: Vytorin: Another Round of Nasty Results
21: Backtracking, Necessary and Unnecessary
18: Lowe's Law of Diurnal Distribution
16: Receptors: Can't Live With 'Em, Can't Understand 'Em
15: Metabolic Hope Springs Eternal
14: Things I Won't Work With: Cyanogen Azide
11: Sharing the Enlightenment
10: More on Outsourcing
09: How's The New Boss Doing?
08: Glaxo Asks the Eurocrats
07: Pfizer's Prospects: Just Ducky
04: Happy Fourth of July
03: I Can Has Ugly Molecules?
02: More Pfizer Layoffs?
01: Leaving Comments: A Fix
01: The Gates Foundation: Dissatisfied With Results?

June 2008
30: Another Alzheimer's Compound Goes Down
27: Unknown - But You Can Buy It
26: Funding in the EU: The Simple Way
25: (No) Anarchy in the EU: A Report From Inside
24: Prasugrel: Come Back This Fall
23: Auroral Activity
19: Anarchy in the EU
18: All The Fat Cells You'll Ever Have - Sort Of
17: Protecting Amyloid's Parent?
16: Alli: "Underwhelming"
13: Elan Tries Again
12: Suits vs. Lab Coats?
11: More On the GSK Layoffs
10: GSK: Money-Green Outside, Pink-Slip Inside
09: An Impressive Nanolist of Nanocitations
06: Resveratrol in Mice
05: Merck, Vioxx: Seventeen and Three
04: Tote That Barge, Lift That Bale
03: Oops
02: A Breath of Fresh Air from Fuji

May 2008
30: Ah, Glassware
29: Nullius in Verba
28: Awash in Yen
27: An Eye For the Numbers
23: Up Close and Personal
22: Killing Proteins Wholesale
21: Lurching Around For Fun and Profit
20: The Miracle Solvent
19: Empty As Can Be
16: Nanotech Stem Cells, Order Now!
15: Copper: A Gentleman's Disagreement
14: Summer Student Time
13: In Which I Hate A Wonder Drug
12: Explaining It All
08: Merck Bails on Natural Products
07: Science By Country
06: Alzheimer's: A Report From the Front
05: Naming of Names
02: "Not Useful" Means "Not Approvable", Right?
01: O Pioneers!

April 2008
30: How Not To Do It: Diazomethane
29: Cordaptive Q and A
28: A Salute
25: Why Buy, Anyway?
24: $720 Million Worth of Sirtuin Research
20: Quick Note
18: Cut It Out. Cut It Out Now.
17: Getting Smarter Already?
16: Fun With Bacteria
15: Walk Around Some
14: Fifteen Minutes Shot
14: A Meditation on Solvents
11: Free Sushi in the Cafeteria!
10: Exubera, Safety, and No Guarantees
09: And You Thought Exubera Was A Disaster Before
09: Another Pop Quiz!
08: Fun With Tunichromes
07: Pre-emption For Real?
04: Another Cholesterol Medication Goes Down (Or Does It)?
03: Whose Guess Is Better?
02: Vytorin Numbers
01: Vytorin: It's A Pity

March 2008
31: Writing It Down
28: RNA Interference: Even Trickier Than You Thought
27: Start Small, Start Right
26: The Lucky Bonus Pack
25: Getting To Lyrica
24: That's Never Gonna Work
21: Pfizer Loses, So Far
20: Anonymity?
19: Now Your Liver Doesn't Have to Make It For You
18: A Solution, Courtesy of the MIT Faculty
17: You Get What You Pay For?
14: Pen and Paper
13: Pfizer vs. the NEJM: A Legal Showdown
12: Taranabant in Trouble?
10: Fill Out Your Pharma Brackets
10: Hits, Misses, and Some More Misses
07: Dissolve Your Troubles Away
06: Fakery And Its Ends
05: Smaller, Wetter, Harder to Work With
04: Off Target? Which Target Did You Mean?
03: Big Steaming Heaps of Fraud

February 2008
29: How Not To Do It: Column Chromatography
28: ApoE4: Test or Not?
27: Antidepressants: Depressing News or Not?
26: Sand Won't Save You This Time
25: More On Merck and Taranabant
21: New Tricks With Glassware
20: What You Become Known For
19: Day Off
15: Putting Out the Inevitable Fires
14: Getting Real With Real Cells
13: One Time Only. Or Maybe Just a Few.
12: DNA Forklifts, DNA Pliers
11: Fast Plaques in a Slow Disease
08: A Look Under the Hood
07: Write It Down, Write it Down
06: Dig the New Breed
05: Room At The Bottom, For Sure
04: How Many PPIs Does the World Need?
01: Commenting Issues
01: A Few Questions For My Fellow Pharma Chemists

January 2008
31: Drugs and Money
30: Recycle, Reuse, Republish
29: The Animal Testing Hierarchy
28: Laissez-Faire?
25: Extractions: A Way of Life
24: Cheap Happiness
23: Making the Adjustment to Smallness
22: These Fragments I Have Shored Against My Ruins
21: Breaking the Contract of Aging
18: Eat It, Breath It, Soak in It?
17: The EU Suspects No One, And Suspects Everyone
16: Judah Folkman
14: Vytorin, Holed Under the Waterline
11: They Can Be Ranked - Somehow
10: Drugs and Money and How It Feels
09: Ah, Politics
08: Rainbows and Fishing Expeditions
06: Dollar, Drugs, and Advertising
04: Plants For Cancer?
03: Top of the Heap
02: Back On the Air

December 2007
21: Winterize Your Ideas
20: Snow Day
19: Scrape Off Some Attitude
18: Hearing Footsteps
17: Le Dernier Cri
14: Biogen's Not For Buying. For Now.
13: Underperforming Triple Bonds
12: Med-Chem Layoffs, On the Front Page
11: A Bad Assay: Better Than None?
10: More Belts Tighten
07: Kids These Days!
05: Avandia: Going Under for the Third Time?
05: Unacceptable
03: The Big and the Little
03: Exciting Nonsense Wins Another One

November 2007
29: Neat! Wish It Were True!
28: Bad Luck For Novartis - And For Diabetics
27: Then I Felt Like Some Watcher of the Skies. . .
26: Still and All
25: You Do The Easy Stuff; I'll Do the Easier
21: Synthetic Prep of the Day: Chocolate Pecan Pie
21: Holiday Break
20: And It Goes Like This!
19: Depressing Figures for Acomplia
15: Quiz Time!
15: And Speaking of Discovering Things. . .
15: Maybe Not Improved, But Definitely New
14: How You Doin'? How's Everybody Doin'?
12: Here Be Chiral Dragons, With Fluorinated Fangs
11: A Real Genetic Headscratcher
09: One Year
08: Dumber in English?
07: Reasons to Be Different
06: Lights, Camera, Pharma!
06: Andy Grove: Rich, Famous, Smart and Wrong
05: Bright Lights and Applause?
04: Nerve, Lots and Lots of Nerve
02: One For the Brave

October 2007
31: Resistant Little Creatures
31: How Not to Do It: Hydrogen Bromide
29: What We Don't Know About Enzymes
29: Bacterial Infection: Better Or Worse Than Cancer?
25: Looking Backwards
24: Come On. Improve, Already.
23: Vial Thirty-Three, And More
22: Surveying the Exubera Crater
18: Understanding Dawns
17: Biogen on the Block?
16: Three Things You Need
15: Checking The Numbers on the Alzheimer's Test
15: Enzyme Humility
12: Unnatural, And Proud Of It
11: Let Us Now Turn To the Example of Yo' Mama
10: Ertl Wins: Down With Witchcraft
09: Nobel Chemistry Odds
09: Blogroll Update
08: Nobel Season
04: No Problem At All
03: More Layoffs, And What They Might Mean
02: Why Now, And Not Before?
01: All Sorts of Holes

September 2007
30: If Not This, What?
27: Thimerosal. Again.
26: Expensive Reading
25: Hey, Graduates! Negotiate Hard, You Hear, Now?
24: More Sirtuins With More Effects
24: Good News From the HR Department!
20: Go With The Er, Flow?
19: Fixing the Patent System?
19: The Good Old CombiChem Days
18: Ugly, But Useful
17: Arsenic, Patents, and the World
13: Don't Step Over It, Even If It's Right in Front of You
12: Drugs From Where?
11: Fresh Air, Or What Passes For It
10: Have We Got A Deal For You!
09: Guess That Market
06: Aromatherapy
06: More Things Than Are Dreamt Of
02: Renin, Wherefore Art Thou, Renin?

August 2007
31: Here It Goes
30: Elbow Room
28: Like Clockwork
27: Oh, Come On
26: Cheer Up
23: ". . . Jobs That Don't Exist"
21: Sorting Through the Piles
21: Ah, Rumors
20: The Current Cancer Long-Jump Record
17: More on Interview Seminars
14: Winning, By Tying Losers Together
13: Pilferage
12: These You Shall Have Always With You
09: Buying What You Can't Make? Or What?
08: Steve Ley, Azadirachtin, and Me (Very Much in That Order)
08: Exubera Spirals Toward the Drainpipe
07: Meet the Blogger?
06: Here, Fix This, Would You?
05: The Choir Hears It Again
03: Not Necessarily So
01: Run! Anthropologists!

July 2007
31: Incomprehension, Out For A Stroll
30: Avandia's Latest Round
27: You Discover It, We Sell It. Deal?
25: From the Sequencer to the Drugstore?
24: Godzilla vs. Mothra? Relman vs. Epstein!
23: Deactivation, After All
22: A Farewell to Tin
19: Hype In Spaaaace!
18: Over There, Behind That Stack of Whatchamacallits
17: Visfatin: Real Or Not?
16: European Drugs, American Drugs
15: Proteomics 101
13: Pour Encourager Les Autres
11: First Impressions
10: Travels In Numerica Deserta
09: Now With Ethyl Mesylate!
08: Starting Up Again

June 2007
26: Two Weeks Off
21: Real Life, Which Costs Real Money
20: Bigger, Tougher, Longer? Or Not?
18: Right Down the Alli
17: Access To Science
15: Rimonabant: Down to Earth
11: Rimonabant, Out In the Light
07: The Chamber of DNA Secrets
06: Massachusetts Moving
06: A Post I've Been Looking Forward to For Months
04: Phase Zero?
03: Pecunia Non Olet?

May 2007
31: The Avandia Wars Continue
29: Knowing What You Know. . .
25: More Avandia, And More on Marketing
24: Avandia: Trouble or Not?
23: Exalted Paper
22: Evolution In Action
20: Little, Big
18: But Enough About You
17: Beta-Secretase: Not So Fast?
16: Sunbeams, Single Electrons, and You
15: Into The Trackless Wilderness
14: Safer Every Day!
10: Alas, Dendreon
09: A New FDA?
09: Blogroll Update
07: Nonsense. On Stilts. Playing a Trumpet.
07: Brazil Raises The Pirate Flag
03: Forewarned is Forearmed
02: Obvious Ain't Obvious No More

April 2007
30: Outsourcing Blues?
29: Time To Conduct Some Business
26: Less Than Zero
25: A New HIV Therapy. Yawn?
24: Put Your Money Down
22: Melting Keys and Squishy Locks
20: Worst Animal Model: Nominations Are Open
19: Let A Thousand Flowers Bloom
19: The Big Time
18: Cro-MagnonDraw
17: The Doctorate and Its Discontents
15: Doctorate or Not?
13: Deep Breaths
12: Layoffs - Again
11: Exubera: This Time With Feeling
11: Amgen: The Pythian Oracle Laughs Again
10: Sulfur, Your Pal. Mostly.
08: Buy! Sell! Shout! Moan!
05: Awful, No Doubt. But Not As Awful as Before?
04: Linkage!
03: Vaccines Everywhere
02: Failure: Not Your Friend, But Definitely Your Companion
01: The HDL Compost Pile

March 2007
30: Rimonabant, Slowly
29: I Want A New Nitro
27: ACS Meetings
26: Vectibix Lurches A Bit
25: Wandering Through the Hydrides
23: Naked Synthesis
22: FDA Advisory Panels: Pay, No Play
20: AGI-1067: Dead or Alive?
19: Scientists, All Over
15: Lousy Reactions: Reader's Choice
14: Schering-Plough Goes Shopping
12: No Shortcuts
11: More Help Wanted?
08: How Not to Do It: More Diethyl Ether (Now With Extra Hardware)
07: Fish Nor Fowl?
07: Quietly Disappearing From the Skies
06: Decisions, Decisions
04: Calcium: A Backwater
01: How Not to Do It: Tertiary Butyllithium

February 2007
28: Have We Got a Job For You!
27: Wrong, But Still Convincing
26: Hedgehogs in Stockholm
25: Biotech's Net Loss?
23: F. A. Cotton, 1930-2007
22: Inspirational Reading?
22: Back From DC
21: CMPI Conference: Critical Path
21: CMPI Conference: CATIE and ALLHAT
21: CMPI Conference: Lunch With the FDA
21: CMPI Conference: Panel on the Politics of Drug Evaluation
21: CMPI Conference: Panel on Media Coverage
20: Something From Nothing
19: You Want Me to Just Talk? No Problem.
18: Wake Up and Smell the Solvents
16: Comments on Comments
14: Gene Patents, Part One: Genes As Chemicals
13: Crichton, Patents, and Genes
12: A Good Day's Work
12: Good Sense Breaks Out, Film at Eleven?
08: Depraved and Deprived
07: There's Toxicity and There's Toxicity
07: Vertex, Hepatitis, and Gripping the Arms of Your Chair
05: Good Mistakes?
05: A Break, Whether I Felt Like It Or Not
04: Going Hollywood, For Our Own Good?
01: How Not To Do It: Ruining Stuff

January 2007
30: BMY-SNY?
29: Open For Business
29: Blogroll Update
28: What Can Academia Do?
25: The Big Picture
25: Way Out Here
24: Back on the Air
17: Pfizer's Pfinances
16: How Not to Do It: Sophomore Organic Edition
15: Novo Nordisk Axes Med-Chem
14: Problems and Solutions
12: Ghost Town
11: An Innocent Question
10: Upside Down Activity
10: Reality, Here In This Little Dish
09: That Smell
08: PLoS One
07: Good Stuff and Bad Stuff
04: Take Your Shots (For Real, This Time?)
03: You'll Be Safe Under Here. Maybe.
02: That Can't Be Right - Try Again
02: And The Winner Is. . .
02: Out With the Old

December 2006
28: Cleans Down to What Should Be the Shine
26: Work At Home! It's Easy; It's Fun!
21: Holiday Schedule
20: Injustice
19: Hi, My Name Is [...]
18: ICOS In Pieces?
14: Love and Anger
13: Ars Longa, But Instructions to Authors Say "Brevis"
11: Torcetrapib: The Foil-Lined Hat Perspective
11: Old School? Same School!
08: Shameless Self-Promotion
07: Are You Experienced?
06: Bigger And Greasier
04: Too Near the Sun?
03: The Torcetrapib Catastrophe
01: Pfizer's Sizing

November 2006
30: The Other Side of the Table
29: Bad Interviews
27: The Litvinenko Case: More On Polonium and Alpha Particles
27: Polonium Poisoning
21: The Paper Mountain
20: Sell! (It's Not Just Me)
17: Ah, the Heck With the Error Bars
15: Vial Thirty-Three: Warp Drive
14: Where Do All The Chemicals Go?
14: Elsewhere
13: The Race Is On
10: Publish, Then Perish
09: Help Wanted - I Hope
08: Watch This Space
08: Links and Such
06: It Went Up Instead of Down
06: Chinese Med-Chem - In China, For Once
02: Hope, Springing Eternal And All That
01: And Thee, O Time
01: You Can't Make Money If You Don't Get Paid

October 2006
30: Blow The Trumpets
29: Family Portraits
26: It Should Work. It Just Doesn't.
25: Mass Spec on Mars
24: Naming of Names
23: Experimental Compound Codes
22: The Unattractive Truth
19: Levoglucosan
18: Peptides as Texts
17: Up Periscope And Fire All Bow Tubes
16: Show What You Know
15: German, Anyone?
12: More Handedness
11: On The Other Hand
10: Five Things I Haven't Used in Years
09: Forty NMR Magnets and 3000 Proteins Later. . .
09: Here and There
05: The Inscrutable French
04: Cheer Up, You Chemists
04: Another Chemistry Prize for Biology
03: Neuropeptide Y Dies, But It Never Surrenders
02: RNA Interference: Film at Eleven
02: Nobel Update: RNAi Wins
01: Test Your Skills!

September 2006
28: The Horse Latitudes
27: Nobel Fever Is Upon Us
26: Smell the Vibrations
25: A Spray-Painted Crystal Ball
24: Touch Me Not
22: Darn Photons
20: Imclone, Drama Queen of Biotech
19: By Any Other Name
18: Tenderbutton Calls It Quits
17: Tough Targets
14: Take Your Shots
13: Spectroscopic Days
12: Walking the Plank at Bristol-Myers Squibb
11: Enzymes Do Whatever They Want To
10: If You Want Your Explanations Overnight, It'll Cost You
07: Inherently Obvious - It's Obviously Inherent
07: Move On, Move On - Nothing To See Here. . .
06: Tell 'Em You Work On Something Else
05: Ariad's Patent Eviscerated
04: Plavix Plot Twists
01: Merck: Unfigure-outable

August 2006
30: Those Darn Invisible Creatures
29: Evil Thoughts of Evil Things
28: Paper on a Shelf
27: Floyd Landis: Could His Cortisone Treatments Exonerate Him?
24: Respect! Honor! Recognition! All For $149.95!
22: Explain This, Hot Shot!
15: Kevin Trudeau Was Born in 1963
15: Here and There
14: Tegenero, In Detail
13: Six Chem-Geek Questions
10: The Great Plavix Disaster
10: Airplanes and Chemicals
09: Ray Kurzweil's Future
08: Back in Court With Ariad and Lilly
07: A Vaccine Against Putting on Weight?
06: Where Do They Come From?
03: The Last Word on Eerie Glowing Labs
02: A Law of the Lab: Yields and Variations
01: Testosterone, Carbon Isotopes, and Floyd Landis

July 2006
31: Hobson's Choice
30: Pfizer's Man at the Top
27: Good News, Now That I Think About It!
26: Pfizer Recalculates
25: The Sun Shines at Pfizer
25: Back To Life
23: Hexacyclinol Rides Again
20: Peptide Craziness
19: Fuzeon's Fallout
18: Getting and Spending
17: Pounding Sand
16: The Future is Unwritten
13: A Friday Linkfest
13: J&J Shrinks Their Labs Again
11: More Purple Radiance
10: Aluminum: Friend or Foe?
09: Down the Chute: Your Call
07: Memo to the Public Relations Department
05: More Statin Skirmishing
04: Now With the Great Taste of Fish!
03: Pyrotechnic Days

June 2006
29: Rimonabant Arrives
28: Part Nine Hundred and Forty Two in a Series. . .
27: Academia in Summertime
26: Vioxx: 18 Months to Trouble?
25: Neurocrine's Choice
22: To The Third Darn Decimal Place
21: Waste O' Time Awards
20: Formally Undecideable
19: Rats Rule, Right?
18: More on Voodoo
15: And 0.04 Molar in Eye of Newt. . .
14: Vox Populi
13: The Fur Continues to Fly
13: Disapproval of Approvability
11: What's German For "Food Fight"?
11: Vial Thirty-Three: The Third Run
08: Peter Kim, So Far
07: Best When Used By. . .
06: Vial Thirty-Three Rides Again
06: Vial Thirty-Three: One Up, One Down
05: Hexacyclinol? Or Not?
04: Resistance Isn't Quite Futile
02: Brief Political Interlude
01: That Fount of Information We Call ASCO

May 2006
31: As Merck Caroms Off Another Tree
30: Things I Won't Work With: Frisky Perchlorates
29: Ask Not
25: Too Big to Discover Anything
25: Back on the Air
23: Can't Buy These Thrills
22: Merck and the Numbers
22: Mid-day Update
21: Chem-Geek Alternate History
20: Minute by Minute
18: A Question For the Crowd
18: Vial Number Thirty-Three
17: Merck's Latest Underwhelming Data
16: The New England Journal And Its PR Flacks
15: Leadership Secrets of the Data Fudgers
14: Cliff Diving
11: A Day at the Rota-Vap
10: A New Route to Tamiflu?
09: Ends, Means, Rats, and Dogs
08: A Natural Wonder Drug - Now What?
07: Yet Another Law
04: Ariad Wins a Round
03: Access to Phase I Drugs: A Constitutional Right?
03: Full Disclosure
03: Have The Rules Changed?
02: Things I'm Glad I Don't Do: Isolating Ciguatoxin
02: Travel

April 2006
30: All Natural
27: Golden Parachute, Still Packed and Ready
26: Jungle Rot
25: A Shot Across the Bow
24: Merck, So Far
23: You Can't Win If You Don't Play
20: Sulfurous Stenches: A Connisseur's Guide
19: Why All the Gloom?
18: There Is a Tide. . .
17: Reading Our Own Press Releases
16: Don't Know. Don't Care?
12: The Process of Process
11: Ariad's Day in Court
10: Linkorama
09: New Frontiers in Self-Deception
06: How Not to Do It: Distilling HMPA
05: Which World Do We Live In, Anyway?
04: Once More Into the Patent Breech
03: More On Doing Away With Patents
02: Down With Patents, Eh?

March 2006
30: Give The People What They Want
30: Missed One!
28: Rioting for Unemployment
27: Cleaning Out the Hood: An Internal Monologue
26: A Word to the Wise About TGN1412
24: Explosion News
24: Can You Say "Uebernahmeangebot"?
23: Crystals of Doubt
22: A Lengthy Day
21: Nitromed's Slow Decline
20: Grad School, Blogged
20: TNG1412: Was There a Warning?
17: Update on TGN1412
16: Price Gouging or Not?
15: No Immunity From Immunity
14: Neowater Replies
13: The Big Statin Pillow Fight
12: Bubble Fusion Implodes
09: Wonder Drug, Indeed
09: Men and Women and Science and Jobs
08: How Not to Do It: Liquid Nitrogen Tanks
08: Things Turn Nasty
06: Man Hands on Misery to Man
05: Journal of Biological Chemical Biochemical Chemical Biology
02: Technical Difficulties
02: Procter and Gamble Throws in the Towel
01: Deception Begins at Home

February 2006
28: More on Outsourcing
27: But At My Back I Always Hear. . .
26: Tied to the Mast
24: What's French for "Trust Us"?
23: Blogroll Revamp
22: NEJM vs. Its Contributors, Round Two
21: Gold and Lasers
20: Rimonabant Bangs Into. . .Something
19: Because I Never Lie, and I'm Always Right
16: What's It Worth to You?
15: Pfizer Takes a Deep Breath
14: First Slide, Please
13: Heart-Warming Stories of Success
12: Kinase Inhibitors: Doomed From the Start?
09: Ban Intelligent Design?
08: Garnier Strikes Back
07: Return of Neowater
06: J&J Shakes Things Up
05: Stream of Consciousness
02: Nanotech Wonder Water?
01: The Good New Days

January 2006
31: Here's A Shovel. Could You Dig Yourself In Some More?
30: Forecast: Rain, Eventually
29: Name Reactions for One Thousand, Alex
26: Ah, It's Fine. Just Send the Darn Thing Out Already.
25: If It's Not One Thing. . .
24: The Examiner Finally Snaps
23: Merck versus the New England Journal
22: Full Disclosure
19: But His Name Lives On. . .
19: Tamiflu: Good For Anything, Or Not?
18: A Scientific Aptitude Test?
17: Gimme That Old Time Reaction
17: Dangerous Thoughts
16: Various Updates
15: The FDA Loosens Its Tie
13: How Not to Do It: Ether Peroxides
12: Plenty of Tar to Go Around
09: Stem Cell Disaster
08: My Shopping List
05: Ugly, But Effective
04: Mice, Humans, and Cancer
03: Pemoline Problems
03: Comments Welcome - Really
02: A Scientist's Resolutions

December 2005
29: Outside Reading
27: What Makes an Ugly Molecule?
23: Sort Of Like A Wine Cellar
22: Poor Put-Upon Intelligent Design
21: Another Shot at Cancer
20: The Dover Decision Comes Down
20: Does Celebrex Have A Future At All?
17: How Not to Do It: Bromine
15: Attack of the Angry Viruses
14: An Expensive Way Back for Celebrex
13: The New England Journal of Legal Immunity?
13: Grand Rounds
12: Play by Play in the Lab
09: A Vioxx Bomb Drops. Or Does It?
07: The Hard News on Cancer
06: Well-Rounded?
06: Grand Rounds Today, and Next Week
05: Home Sweet Home
04: Not On the Same Page
02: The Bell Finally Tolls for Peter Rost
01: Rigel's Puzzling Failure

November 2005
30: Okadaic Acid Makes Vanity Fair
30: Merck Update
29: Ghrelin and Obestatin
28: Merck, Finally
27: Hire the Thoroughbreds?
25: Instead of Working
22: Serono's Suitors
21: Run, Do Not Walk, To The Nearest Exit
21: Old Standbys
20: Sir2 Surprise
17: A Man, A Book, and a Plan. Several Plans.
16: What Sort of Training?
15: Statin Showdown
14: One Darn Miracle After Another
13: Arcadia's Furnishings
11: Gene to Drug: You Bet
10: . . .And That Settles It
09: Cash For Vaccines
08: University of Drug Discovery?
07: Intelligent Design, Molecule By Molecule
06: The Dover Decision
03: Merck Off the Mat
02: The Flu Plan, Part Two: Antiviral Drugs
02: The Flu Plan, Part One: Vaccines
01: Molecular Modeling Cage Match

October 2005
31: Five Questions
30: Gooooaaaal!
28: Pargluva Goes Down?
27: Imclone Revisited
26: The Latest in Pharmaceutical Technology
25: Start Your Engines
24: Hype or Hope?
23: The Tar Pit Beckons
20: This Had Better Be Good
19: Complaints From a Fossil
19: Procrastination Assistance
18: Waiting for Pargluva
17: James Cramer, Biocryst, and You
16: Matthias Rath, Pioneer
13: Buy! It's More Expensive Than Usual!
12: The Undefeated Brazilian Team
11: The Old Stuff
10: Time and Chance
09: Needs and Wants
06: The Great Divide
06: Outside Reading, and Plenty of It
05: Human Genome Science Hits the Wall
05: Metathesis Nobel!
03: Where Do the Good Ones Go?
03: Well Deserved
02: A Piece of the Action

September 2005
30: And Another Thing. . .
29: The Hazards of Molecular Modeling
28: Clamping Down, or Loosening Up?
27: Tribes
26: Antivirals "Gathering Dust"?
25: Report From What I Think is the Frontier
22: By a Nose in a Head to Head
21: No Clear Winners
20: Say It Again!
19: Klotho: Sooner Than You Think?
18: A Sensitive Guy
15: Pretty Much the Reason You'd Think
15: Here and There
13: It Pours on Ligand
12: ". . .And to Furbish Falsehoods For a Magazine"
11: Remind Me Not to Do This Again
08: Muraglitazar's Turn
07: The Tiniest Doors Begin to Open
06: